Form 8-K - Current report:
SEC Accession No. 0001213900-14-000160
Filing Date
2014-01-13
Accepted
2014-01-13 07:00:39
Documents
3
Period of Report
2014-01-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT f8k011014_actiniumpharma.htm 8-K 29772
2 PRESS RELEASE OF ACTINIUM PHARMACEUTICALS f8k011014ex99i_actinium.htm EX-99.1 21608
3 img01.jpg GRAPHIC 7031
  Complete submission text file 0001213900-14-000160.txt   62430
Mailing Address 501 FIFTH AVENUE, 3RD FLOOR NEW YORK NY 10017
Business Address 501 FIFTH AVENUE, 3RD FLOOR NEW YORK NY 10017 212-300-2131
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-52446 | Film No.: 14523167
SIC: 6770 Blank Checks